
CheckMate 7A8
NCT04075604
A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer
Status:
Opening Soon

II
Phase

Neoadjuvant
Line of Therapy

Early Cancer
Disease Stage

Biomarker(s)
ER+, HER2-
Investigational
Product
Nivolumab, Palbociclib & Anastrozole
Treatment Arms
oNivolumab+Palbociclib+Anastrozole
o Palbociclib+ANZ then Nivolumab+Palbociclib+ANZ
o Palbociclib+ANZ